HomeCompareNARI vs EQR

NARI vs EQR: Dividend Comparison 2026

NARI yields 2.50% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $24.4K in total portfolio value
10 years
NARI
NARI
● Live price
2.50%
Share price
$79.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.4K
Annual income
$293.91
Full NARI calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — NARI vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNARIEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NARI + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NARI pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NARI
Annual income on $10K today (after 15% tax)
$212.58/yr
After 10yr DRIP, annual income (after tax)
$249.82/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $4,404.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NARI + EQR for your $10,000?

NARI: 50%EQR: 50%
100% EQR50/50100% NARI
Portfolio after 10yr
$35.6K
Annual income
$2,884.76/yr
Blended yield
8.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

NARI
Analyst Ratings
4
Buy
8
Hold
Consensus: Hold
Price Target
$67.56
-15.5% upside vs current
Range: $50.00 — $86.00
Altman Z
11.2
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NARI buys
0
EQR buys
0
No recent congressional trades found for NARI or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNARIEQR
Forward yield2.50%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$23.4K$47.8K
Annual income after 10y$293.91$5,475.61
Total dividends collected$2.7K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$67.56$70.35

Year-by-year: NARI vs EQR ($10,000, DRIP)

YearNARI PortfolioNARI Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$10,950$250.09$11,380$679.82$430.00EQR
2$11,973$255.94$13,014$837.25$1.0KEQR
3$13,072$261.53$14,961$1,036.20$1.9KEQR
4$14,254$266.87$17,297$1,289.22$3.0KEQR
5$15,524$271.96$20,121$1,613.15$4.6KEQR
6$16,887$276.81$23,561$2,030.84$6.7KEQR
7$18,351$281.42$27,783$2,573.54$9.4KEQR
8$19,921$285.81$33,013$3,284.39$13.1KEQR
9$21,606$289.97$39,547$4,223.51$17.9KEQR
10$23,412$293.91$47,791$5,475.61$24.4KEQR

NARI vs EQR: Complete Analysis 2026

NARIStock

Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Full NARI Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this NARI vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NARI vs SCHDNARI vs JEPINARI vs ONARI vs KONARI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.